{"slug":"thymulin","seoKey":"thymulin","inn":"Nonathymulin","displayName":"Thymulin","codes":["FTS"],"synonyms":["Nonathymulin","Facteur thymique sérique","Serum thymic factor","Serum-Thymusfaktor","Zinc-thymulin","Zink-Thymulin","Thymuline","Thymulin acetate","Circulating thymic factor","Oligopeptide thymic factor"],"legalClass":"research_chemical","identifiers":{"cas":"63958-90-7","pubchemCid":3085284,"unii":"9H198D04WL","inchikey":"LIFNDDBLJFPEAN-BPSSIEEOSA-N","formula":"C33H54N12O15","molecularWeight":858.9,"sequence":"EAKSQGGSN"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: no approved product carries this active ingredient. Three queries of the agency's open interfaces returned no match on 2026-09-20 — the approval database, the labelling archive and the recall database — while a control query with identical syntax returned one match, so the method was working. Two positive register entries exist, and neither is an approval. First, the national drug code directory lists exactly two records, both of the type bulk ingredient, from a Chinese peptide manufacturer and a United States ingredient distributor; listing a raw material is a manufacturer's registration duty and says nothing about quality or usability. Second, and more telling, the list of bulk drug substances nominated for use in pharmacy compounding under section 503A places 'thymulin acetate' in category 3, meaning nominated without adequate support: the agency states there is insufficient supporting information for it to evaluate the substance at all. The corresponding list for outsourcing facilities does not mention it. No warning letter names the substance; letters found under a similar name concern a different substance.","source":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"market":"EU","status":"not_approved","note":"Not approved: no centralised authorisation, no assessment report, no withdrawn application and no orphan designation. Both official datasets were downloaded and searched in full on 2026-09-20, with no match for any spelling of the name, while two control substances were found in the same file. IMPORTANT DISTINCTION: in France two active homeopathic registrations do exist under the name 'thymuline', held by two homeopathic manufacturers, registered nationally in 2014 and 2019 and both marketed. A homeopathic registration is a simplified procedure that expressly requires no therapeutic indication to be claimed and covers dilutions from 4CH upwards, at which point virtually no molecule of the starting substance remains. It is therefore not a marketing authorisation of the peptide, carries no prescription status, and says nothing about the injectable form.","source":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx"},{"market":"DE","status":"not_approved","note":"Not approved and not marketable. With neither a European nor a national authorisation, every injectable preparation is an unauthorised medicinal product and placing it on the market falls under the authorisation requirement of the medicines act. Importing it privately as a research chemical does not meet the narrow conditions for single-patient import against a prescription through a pharmacy. It is absent from the prescription-only annex, which changes nothing: that annex governs the prescription status of authorised substances, not the question of authorisation. It is likewise absent from the annex to the anti-doping act, whose only thymus-related entry concerns thymosin beta-4 and its derivatives; unlike the international prohibited list, that annex has no catch-all provision, so its criminal possession and trading offences do not apply here. Full-text checks of both instruments on 2026-09-20, with control substances found in each.","source":"https://www.gesetze-im-internet.de/amvv/anlage_1.html"},{"market":"UK","status":"not_approved","note":"No authorisation identified. IMPORTANT CAVEAT: this is not a primary-verified negative finding. The regulator's product search returned HTTP 200 on 2026-09-20 but renders its result list only through client-side scripting; the delivered HTML contained nothing but scaffolding, and the underlying search interface answered with HTTP 403. No result could therefore be read from the working environment. The absence of an authorisation is plausible and consistent with the European finding, but it rests on that Union-wide picture rather than on the British register itself. Supply would at most be conceivable as an unlicensed medicine against a named-patient prescription.","source":"https://products.mhra.gov.uk/search/?search=thymulin"},{"market":"AU","status":"not_approved","note":"Not scheduled — a primary-verified negative finding, and a notable contrast. The full text of the Poisons Standard in force was searched on 2026-09-20 with no match for the substance under either of its names, while control substances returned three matches each, so the search was working. Ipamorelin, BPC-157, CJC-1295 and thymosin beta-4 are all named there in Schedule 4 and Appendix D, where mere possession without authority is unlawful; this substance is not, and no catch-all provision would capture it. CAVEAT: a separate query of the register of therapeutic goods was not carried out successfully, so a product registration could be neither confirmed nor excluded. An unregistered therapeutic good may not be supplied there in any case.","source":"https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty list on 2026-09-20. A control query for a comparable peptide returned two matches in the same call, so the negative finding is sound.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=thymulin"},{"market":"CH","status":"not_approved","note":"Not approved: the extended list of authorised human medicines, which carries an international-non-proprietary-name column, was downloaded and searched in full on 2026-09-20, with no match for any spelling of the name nor for any of the neighbouring thymus peptides. Two control substances returned fifteen and nineteen matches in the same file, so it was fully loaded and searchable.","source":"https://www.swissmedic.ch/dam/swissmedic/de/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/Erweiterte_Arzneimittelliste%20HAM.xlsx"}],"devStage":"discontinued","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/3085284","https://pubchem.ncbi.nlm.nih.gov/compound/71300623"],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Thymulin: what the trials show, status and safety","summary":"Thymulin is a hormone made by the thymus gland, built from nine amino acids and active only while a zinc ion is bound to it. French researchers described it in the 1970s and tested it in people between 1982 and 1989. One trial in rheumatoid arthritis was positive, was never repeated, and never published its participant count. The one trial in multiple sclerosis, in 40 people, failed on all three measures. No country has approved it, and its half-life in people has never been measured.","updated":"2026-09-20","url":"https://mypep.app/peptides/thymulin"}